Fresenius Kabi is offering Posaconazole Injection, a generic for Noxafil, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system.
Posaconazole Injection is the newest addition to the company’s portfolio of more than 30 anti-infective molecules.
[Read more: Fresenius Kabi intros generic Tepadina]
Available in a 300 mg per 16.7 ml vial, Posaconazole Injection is used to treat invasive aspergillosis, a serious fungal infection, in adults and teenagers aged 13 years old and older. It also is used to prevent invasive aspergillus and candida infections in patients who are severely immunocompromised, including adults and pediatric patients aged 2 years old and older.
“The introduction of Posaconazole Injection reflects Fresenius Kabi’s ongoing commitment to expanding our portfolio of affordable generic options for the treatment and/or prevention of life-threatening infections,” said John Ducker, president and CEO of Fresenius Kabi USA.
Posaconazole Injection is produced at the company’s pharmaceutical production site in Grand Island, N.Y.
[Read more: Fresenius Kabi intros generic Foscavir]
“We are doubling our U.S. manufacturing capacity to enhance the resilience of our supply chain, which helps assure fast, reliable service for our customers and the patients they serve,” said Lindsey Thomas, senior vice president of marketing of Fresenius Kabi USA. “Our investments will help patients gain access to the treatments they need—when and where they need them most.”